Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 8 | Journal of Experimental & Clinical Cancer Research

Fig. 8

From: Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment

Fig. 8

A combinatory approach to reverse the post-surgical immunity. A-B) Representative confocal microscopy images of coronal brain slices from animals who had received resection or resection plus treatment(s). Sections were immuno-stained against MHCII (lower panel A, in purple), ARG-1 (lower panel B, in white) and TMEM119 (lower panels A and B, in green) while tumor cells transgenetically expressed DsRed (in red in the upper panels A and B). MHCII+/TMEM119+ cells (panel A) and ARG-1+/TMEM119+ (panel B) are represented in cyan in the lower panels to evaluate the level of microglial activation and the anti-inflammatory status, respectively. Scale bar: 300 µm for upper panels, 30 µm for lower panels; C) Quantifications of the densities of each cell sub-population (mean ± SEM, n = 4; Unpaired t test, # 0.05 < p < 0.06; *p < 0.05; ****p < 0.0001)

Back to article page